Cardiovascular disease is the leading cause of death and disproportionately prevalent in
patients with kidney disease. Spironolactone has been shown to improve survival in the
general population with heart failure by up to 30%. We wish to study the safety and
tolerability of aldosterone blockade with spironolactone on cardiac function in a high risk
population of patients on hemodialysis. We will study and closely monitor subjects over a
period of 12 months, during which they will be receiving spironolactone for a period of 6
months.
Phase:
Phase 4
Details
Lead Sponsor:
State University of New York - Upstate Medical University